Gilead: Acquire, or get acquired?
For some time now, investors have been watching and waiting to see which biotechs, if any, Gilead Sciences might acquire. Indeed, when CEO Dan O'Day popped into the STAT Summit in Cambridge in November, he acknowledged the company, which is sitting on a ton of cash, might be in an "acquisitive mode."
Lately, though, another question has arisen among investors: Might Gilead itself be a takeover target? That chatter and a suggestion by Jefferies analyst Michael Yee sent Gilead's stock shooting higher late last week.
A health care investor, asked his view on the matter by STAT's Adam Feuerstein, said talk of an acquisition was preposterous. But that doesn't mean it doesn't tell us something about investor views on Gilead these days.
Read more.
Lately, though, another question has arisen among investors: Might Gilead itself be a takeover target? That chatter and a suggestion by Jefferies analyst Michael Yee sent Gilead's stock shooting higher late last week.
A health care investor, asked his view on the matter by STAT's Adam Feuerstein, said talk of an acquisition was preposterous. But that doesn't mean it doesn't tell us something about investor views on Gilead these days.
Read more.
.png)
No hay comentarios:
Publicar un comentario